Imunon, Inc.(IMNN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMNN Imunon, Inc.

Trading 01-15 14:25:34 EST

3.46

-0.23

-6.23%

High3.63	Low3.40	Vol54.87K
Open3.58	D1 Closing3.69	Amplitude6.10%
Mkt Cap11.77M	Tradable Cap11.65M	Total Shares3.40M
T/O192.23K	T/O Rate1.63%	Tradable Shares3.37M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMNN","market":"US","secType":"STK","nameCN":"Imunon, Inc.","latestPrice":3.46,"timestamp":1768504942264,"preClose":3.69,"halted":0,"volume":54867,"delay":0,"floatShares":3366400,"shares":3400400,"eps":-9.544866,"marketStatus":"Trading","change":-0.23,"latestTime":"01-15 14:25:34 EST","open":3.58,"high":3.625,"low":3.4,"amount":192232.3668621,"amplitude":0.060976,"askPrice":3.46,"askSize":13,"bidPrice":3.35,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-9.544866,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1768510800000},"marketStatusCode":2,"adr":0,"listingDate":959745600000,"exchange":"NASDAQ","adjPreClose":3.69,"preHourTrading":{"tag":"盘前","latestPrice":3.6484,"preClose":3.69,"latestTime":"09:00 EST","volume":502,"amount":1832.139862,"timestamp":1768485602817},"postHourTrading":{"tag":"盘后","latestPrice":3.75,"preClose":3.65,"latestTime":"19:50 EST","volume":407,"amount":1526.34,"timestamp":1768438226601},"volumeRatio":1.204577},"requestUrl":"/m/hq/s/IMNN","defaultTab":"news","newsList":[{"id":"2601460384","title":"BRIEF-Imunon Inc - Interim CFO Kimberly Graper To Resign January 14, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2601460384","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601460384?lang=en_us&edition=fundamental","pubTime":"2026-01-08 06:29","pubTimestamp":1767824960,"startTime":"0","endTime":"0","summary":"BRIEF-Imunon Inc - Interim CFO Kimberly Graper To Resign January 14, 2026 - SEC FilingJan 8  - Imunon Inc IMNN.O:IMUNON INC - INTERIM CFO KIMBERLY GRAPER TO RESIGN JANUARY 14, 2026 - SEC FILINGIMUNON INC - APPOINTS JEFFREY CHURCH AS INTERIM CFO - SEC FILINGFurther company coverage: IMNN.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y81PI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN","BK4139"],"gpt_icon":0},{"id":"2601384515","title":"Imunon Inc. Sets $30,000 Monthly Retainer for Interim CFO Church","url":"https://stock-news.laohu8.com/highlight/detail?id=2601384515","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601384515?lang=en_us&edition=fundamental","pubTime":"2026-01-08 06:16","pubTimestamp":1767824175,"startTime":"0","endTime":"0","summary":"Imunon Inc. has amended its consulting agreement with Mr. Church, effective January 14, 2026. Under the new terms, Mr. Church will receive a monthly retainer of $30,000 for his consulting services, with an additional payment of $250 for each hour of work exceeding 40 hours per month during the extended consulting period. This agreement may be terminated by either party with 10 business days' notice.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL6bxn5P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2595790783","title":"Imunon to Raise Roughly $7 Million From Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2595790783","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595790783?lang=en_us&edition=fundamental","pubTime":"2025-12-30 22:03","pubTimestamp":1767103390,"startTime":"0","endTime":"0","summary":"Imunon  said Tuesday it expects to raise about $7 million through a registered direct offering led by a single healthcare-focused institutional investor.The company will sell 1,939,114 common shares, or pre-funded warrants in lieu of shares, along with warrants to buy an equal number of shares, it said.The securities are priced at $3.61 per share and accompanying warrant, Imunon said, adding that the warrants are exercisable immediately at $3.482 per share and will expire five years from the issuance date.The offering will likely close around Wednesday, the company added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2595797701","title":"Imunon Announces Pricing of $7.0 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2595797701","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595797701?lang=en_us&edition=fundamental","pubTime":"2025-12-30 21:30","pubTimestamp":1767101400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nTUABDK59R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2595731566","title":"Imunon Advances Pivotal Phase 3 OVATION 3 Study for IMNN-001 in Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2595731566","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595731566?lang=en_us&edition=fundamental","pubTime":"2025-12-30 00:10","pubTimestamp":1767024615,"startTime":"0","endTime":"0","summary":"Imunon Inc. has announced continued progress in its pivotal Phase 3 OVATION 3 clinical study evaluating IMNN-001 for ovarian cancer treatment. The company reported ongoing enrollment and stated that interim analyses could potentially enable early trial completion and a Biologics License Application  filing for the HRD+ patient population. Preliminary data from a minimal residual disease  study have shown promising results, including lower MRD positivity rates, improved complete response scores at cytoreduction, and a higher probability of progression-free survival with IMNN-001 compared to the control arm. The company plans to present additional data at major conferences in the future. IMNN-001 has received Fast Track and Orphan Drug designations and continues to demonstrate a positive tolerability profile.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL4zHVjB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","NDAQ","BK4585","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","LU0314104364.USD","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","IMNN","LU2210150020.SGD","SG9999014013.SGD","SG9999014039.USD"],"gpt_icon":0},{"id":"2583665288","title":"Imunon, Inc. Faces Market Volatility: The Impact of Short Selling on Stock Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=2583665288","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583665288?lang=en_us&edition=fundamental","pubTime":"2025-11-16 14:01","pubTimestamp":1763272901,"startTime":"0","endTime":"0","summary":"Imunon, Inc. (IMNN) has disclosed a new risk, in the Share Price & Shareholder Rights category. Imunon, Inc. faces a significant risk from market a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/imunon-inc-faces-market-volatility-the-impact-of-short-selling-on-stock-prices?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/imunon-inc-faces-market-volatility-the-impact-of-short-selling-on-stock-prices?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNN","BK4139"],"gpt_icon":0},{"id":"2583054575","title":"Alliance Global Partners Remains a Buy on Imunon (IMNN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583054575","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583054575?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:35","pubTimestamp":1763123733,"startTime":"0","endTime":"0","summary":"In a report released today, James Molloy from Alliance Global Partners reiterated a Buy rating on Imunon, with a price target of $12.00. According ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alliance-global-partners-remains-a-buy-on-imunon-imnn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alliance-global-partners-remains-a-buy-on-imunon-imnn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNN","BK4139"],"gpt_icon":0},{"id":"2583598329","title":"Corrected-Imunon Inc - Reports Q3 Loss per Share (Not 'EPS') $1.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2583598329","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583598329?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:06","pubTimestamp":1763039213,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL8N3WP13W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2583756026","title":"Imunon reports Q3 EPS ($1.16) vs ($3.76) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2583756026","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583756026?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:50","pubTimestamp":1763038255,"startTime":"0","endTime":"0","summary":"“IMUNON (IMNN) is rapidly advancing a potential breakthrough for women with newly diagnosed advanced ovarian cancer-a disease with no meaningful fr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/imunon-reports-q3-eps-1-16-vs-3-76-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/imunon-reports-q3-eps-1-16-vs-3-76-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNN","BK4139"],"gpt_icon":0},{"id":"2583560532","title":"Imunon Inc. reports third quarter net loss of $3.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583560532","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583560532?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:49","pubTimestamp":1763038157,"startTime":"0","endTime":"0","summary":"Imunon Inc. reported a net loss of $3.4 million, or $1.16 per share, for the third quarter of 2025, compared to a net loss of $4.8 million, or $3.8 per share, in the same period of 2024. Operating expenses were $3.5 million for the third quarter of 2025, down 30% from $5.0 million in the third quarter of 2024. During the period, Imunon advanced its Phase 3 clinical development of lead candidate IMNN-001 for newly diagnosed advanced ovarian cancer, expanded trial sites, and reported enrollment exceeding expectations. The company also presented translational data from the Phase 2 OVATION 2 study and continued to seek strategic partnerships to support its PlaCCine platform for vaccines and oncology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL4ntFXX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2583603455","title":"Imunon Q3 EPS $(1.16) Beats $(1.80) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583603455","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583603455?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:46","pubTimestamp":1763037999,"startTime":"0","endTime":"0","summary":"Imunon Q3 EPS $(1.16) Beats $(1.80) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48830942/imunon-q3-eps-1-16-beats-1-80-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2583560533","title":"Imunon Inc - Reports Q3 EPS $1.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2583560533","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583560533?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:45","pubTimestamp":1763037900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA115TVB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMNN","BK4139"],"gpt_icon":0},{"id":"2582765948","title":"Imunon Launches Phase 3 Trial of IMNN-001 Immunotherapy for Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2582765948","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582765948?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:35","pubTimestamp":1762778154,"startTime":"0","endTime":"0","summary":"Imunon Inc. has announced updates on the clinical progress of its novel DNA-mediated immunotherapy, IMNN-001, for the treatment of newly diagnosed advanced ovarian cancer. The company is currently conducting a Phase 3 pivotal trial, OVATION 3, with site expansions and patient enrollment reportedly exceeding expectations. During an R&D Day event, Imunon presented new data from the Phase 2 OVATION 2 Study and a minimal residual disease  study, highlighting IMNN-001's impact on activating both innate and adaptive immune systems and remodeling the tumor microenvironment. The event included presentations from key opinion leaders and provided updates on clinical milestones, with additional results and materials made available via the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLVNDTw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2582187507","title":"Imunon R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women With Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2582187507","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582187507?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:30","pubTimestamp":1762777800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUA2BHRX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMNN","BK4139"],"gpt_icon":0},{"id":"2581988118","title":"Imunon Inc  expected to post a loss of $1.81 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581988118","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581988118?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:54","pubTimestamp":1762527257,"startTime":"0","endTime":"0","summary":"Imunon Inc  expected to post a loss of $1.81 a share - Earnings Preview Imunon Inc IMNN.OQ IMNN.O is expected to  show no change in quarterly revenue when it reports  results on November 13 for the pe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ21N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2581088330","title":"BRIEF-Imunon Research And Development Day: Opportunity To Hear Clinical Trial Investigators Discuss Significant Potential Of IMNN-001 To Redefine Ovarian Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2581088330","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581088330?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:12","pubTimestamp":1762521166,"startTime":"0","endTime":"0","summary":"BRIEF-Imunon Research And Development Day: Opportunity To Hear Clinical Trial Investigators Discuss Significant Potential Of IMNN-001 To Redefine Ovarian Cancer TreatmentNov 7 (Reuters) - Imunon Inc I","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUA171MKH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2581887258","title":"Imunon R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of Imnn-001 to Redefine Ovarian Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2581887258","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581887258?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:05","pubTimestamp":1762520700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUA171MKH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2580219307","title":"Imunon Inc  expected to post a loss of $1.81 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580219307","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580219307?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:01","pubTimestamp":1762178464,"startTime":"0","endTime":"0","summary":"Imunon Inc  expected to post a loss of $1.81 a share - Earnings Preview Imunon Inc IMNN.OQ IMNN.O is expected to  show no change in quarterly revenue when it reports  results on November 5 (estimated)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF188:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2579268149","title":"IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2579268149","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579268149?lang=en_us&edition=fundamental","pubTime":"2025-10-30 20:00","pubTimestamp":1761825600,"startTime":"0","endTime":"0","summary":"Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress 2025 LAWRENCEVILLE, N.J., Oct.  30, 2025  (GLOBE NEWSWIRE) -- IMUNON, I","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177359/0/en/IMUNON-to-Present-Phase-3-OVATION-3-Study-of-IMNN-001-in-Advanced-Ovarian-Cancer-at-IGCS-2025-Annual-Global-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4195","BK4139","BK4097","BK4211","IMNN","PFS"],"gpt_icon":0},{"id":"2577583925","title":"IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2577583925","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577583925?lang=en_us&edition=fundamental","pubTime":"2025-10-23 22:01","pubTimestamp":1761228060,"startTime":"0","endTime":"0","summary":"IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per plan LAWRENCEVILLE, N.J., Oct.  23, 2025  (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in P","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/23/3172179/0/en/IMUNON-to-Present-New-Translational-Data-from-Phase-2-OVATION-2-Study-of-IMNN-001-at-SITC-40th-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B12V2V27.USD","BK4139","IE00BYTNYN87.SGD","IMNN","SG9999011746.SGD","OS","ACT","BK4097","BK4080","BK4231","SITC","BK1541","IE00BYQNZ168.SGD","BK1103","01308"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.imunon.com","stockEarnings":[{"period":"1week","weight":-0.0689},{"period":"1month","weight":-0.0806},{"period":"3month","weight":-0.2787},{"period":"6month","weight":-0.4931},{"period":"1year","weight":-0.6868},{"period":"ytd","weight":-0.042}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0141},{"period":"3month","weight":0.045},{"period":"6month","weight":0.1},{"period":"1year","weight":0.1858},{"period":"ytd","weight":0.0124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.411765,"avgChangeRate":0.084982},{"month":2,"riseRate":0.375,"avgChangeRate":0.031658},{"month":3,"riseRate":0.515152,"avgChangeRate":0.050761},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.048439},{"month":5,"riseRate":0.352941,"avgChangeRate":0.12499},{"month":6,"riseRate":0.441176,"avgChangeRate":-0.05147},{"month":7,"riseRate":0.382353,"avgChangeRate":-0.054834},{"month":8,"riseRate":0.411765,"avgChangeRate":0.007426},{"month":9,"riseRate":0.294118,"avgChangeRate":-0.078238},{"month":10,"riseRate":0.294118,"avgChangeRate":-0.043613},{"month":11,"riseRate":0.294118,"avgChangeRate":-0.024039},{"month":12,"riseRate":0.441176,"avgChangeRate":-0.041409}],"exchange":"NASDAQ","name":"Imunon, Inc.","nameEN":"Imunon, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Imunon, Inc.(IMNN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Imunon, Inc.(IMNN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Imunon, Inc.,IMNN,Imunon, Inc.股票,Imunon, Inc.股票老虎,Imunon, Inc.股票老虎国际,Imunon, Inc.行情,Imunon, Inc.股票行情,Imunon, Inc.股价,Imunon, Inc.股市,Imunon, Inc.股票价格,Imunon, Inc.股票交易,Imunon, Inc.股票购买,Imunon, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Imunon, Inc.(IMNN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Imunon, Inc.(IMNN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction